There has never been a better time to sell or buy drug royalties, says industry veteran
IAM speaks to leading deal-maker David MacNaughtan about his new fund and the growth of this form of life sciences IP monetisation
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.